BG103434A - Амиди инхибиращи апо в-секреция/мтр, фармацевтичен състав и използването им - Google Patents
Амиди инхибиращи апо в-секреция/мтр, фармацевтичен състав и използването имInfo
- Publication number
- BG103434A BG103434A BG103434A BG10343499A BG103434A BG 103434 A BG103434 A BG 103434A BG 103434 A BG103434 A BG 103434A BG 10343499 A BG10343499 A BG 10343499A BG 103434 A BG103434 A BG 103434A
- Authority
- BG
- Bulgaria
- Prior art keywords
- inhibitors
- compounds
- apo
- secretion
- hmg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретението се отнася до съединения с формула@@или до техни стереоизомери, фармацевтично приемливи соли и хидрати. Съединенията са Аро В/МТР инхибитори и могат да се използват за лечение на заболявания като атеросклероза, панкреатит, затлъстяване,хиперхолестеролемия, хипертриглицеридемия, хиперлипидемия и диабет. В комбинация с други фармацевтични средства те са полезни като инхибитори на биосинтеза на холестерол и инхибитори на абсорбцията на холестерол, по-специално инхибитори на HMG-CoA редуктаза и на HMG-CoA синтаза, инхибитори на геннаекспресия на HMG-CoA редуктаза, СЕРТ инхибитори, усилващи секрецията на жлъчна киселина, фибрати, инхибитори на абсорбцията на холестерол, АСАТ инхибитори, инхибитори на сквален синтетаза, йонообменни смоли, антиокислители и ниацин. Изобретението сеотнася също до междинни съединения и метод за получаване на посочените съединения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3230796P | 1996-11-27 | 1996-11-27 | |
PCT/IB1997/001368 WO1998023593A1 (en) | 1996-11-27 | 1997-11-03 | Apo b-secretion/mtp inhibitory amides |
Publications (1)
Publication Number | Publication Date |
---|---|
BG103434A true BG103434A (bg) | 2000-07-31 |
Family
ID=21864233
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108830A BG108830A (bg) | 1996-11-27 | 1999-05-26 | Метод за получаване на 4' - трифлуорометилбифенил-2-карбоксамидо-(1,2,3,4-тетрахидроизохинолин-6-ил) и негови соли |
BG103434A BG103434A (bg) | 1996-11-27 | 1999-05-26 | Амиди инхибиращи апо в-секреция/мтр, фармацевтичен състав и използването им |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108830A BG108830A (bg) | 1996-11-27 | 1999-05-26 | Метод за получаване на 4' - трифлуорометилбифенил-2-карбоксамидо-(1,2,3,4-тетрахидроизохинолин-6-ил) и негови соли |
Country Status (34)
Country | Link |
---|---|
US (1) | US6121283A (bg) |
EP (1) | EP0944602A1 (bg) |
JP (1) | JP3270764B2 (bg) |
KR (1) | KR100334567B1 (bg) |
CN (2) | CN1238764A (bg) |
AP (1) | AP804A (bg) |
AR (1) | AR010309A1 (bg) |
AU (1) | AU716151B2 (bg) |
BG (2) | BG108830A (bg) |
BR (1) | BR9714364A (bg) |
CA (1) | CA2272719C (bg) |
CZ (1) | CZ292160B6 (bg) |
DZ (1) | DZ2358A1 (bg) |
EA (1) | EA001539B1 (bg) |
GT (1) | GT199700122A (bg) |
HN (1) | HN1997000144A (bg) |
HR (1) | HRP970642A2 (bg) |
ID (1) | ID18995A (bg) |
IL (1) | IL129744A0 (bg) |
IS (1) | IS5040A (bg) |
MA (1) | MA26451A1 (bg) |
NO (1) | NO312760B1 (bg) |
NZ (1) | NZ335162A (bg) |
OA (1) | OA11050A (bg) |
PA (1) | PA8441601A1 (bg) |
PE (1) | PE17199A1 (bg) |
SK (1) | SK65499A3 (bg) |
TN (1) | TNSN97193A1 (bg) |
TR (1) | TR199901180T2 (bg) |
TW (1) | TW502023B (bg) |
UY (1) | UY24789A1 (bg) |
WO (1) | WO1998023593A1 (bg) |
YU (1) | YU23499A (bg) |
ZA (1) | ZA9710641B (bg) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US5919795A (en) * | 1995-06-07 | 1999-07-06 | Pfizer Inc. | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion |
GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
US5968950A (en) * | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
AU4543899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
EA200100428A1 (ru) | 1998-10-08 | 2001-10-22 | Смитклайн Бичам Плс | Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты) |
GB9826412D0 (en) * | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
NZ512536A (en) * | 1998-12-23 | 2003-11-28 | G | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
WO2000038725A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations for cardiovascular indications |
DE19929012A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln |
DE19929031A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln |
DE19929065A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
AU6824700A (en) * | 1999-07-20 | 2001-02-05 | Novartis Ag | Organic compounds |
IL139449A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Use of apo b secretion/mtp inhibitors |
CA2324801A1 (en) * | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Use of apo b secretion/mtp inhibitors and anti-obesity agents |
IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
CA2324800A1 (en) * | 1999-11-10 | 2001-05-10 | Mary Anne Hickman | Use of apo b secretion/mtp inhibitors |
ES2240420T3 (es) * | 2000-01-18 | 2005-10-16 | Novartis Ag | Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b. |
JP4009460B2 (ja) * | 2000-03-14 | 2007-11-14 | アクテリオン ファマシューティカルズ リミテッド | 1,2,3,4−テトラヒドロイソキノリン誘導体 |
WO2001077077A1 (en) * | 2000-04-10 | 2001-10-18 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
GB0013346D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
WO2002014277A1 (fr) * | 2000-08-10 | 2002-02-21 | Tanabe Seiyaku Co., Ltd. | Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci |
WO2002014276A1 (fr) * | 2000-08-10 | 2002-02-21 | Tanabe Seiyaku Co., Ltd. | Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese |
WO2002020009A1 (fr) * | 2000-09-01 | 2002-03-14 | Sankyo Company, Limited | Compositions medicales |
JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
US20040058903A1 (en) * | 2000-10-05 | 2004-03-25 | Hisashi Takasugi | Benzamide compounds as apo b secretion inhibitors |
JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
JP2004532856A (ja) * | 2001-04-30 | 2004-10-28 | 藤沢薬品工業株式会社 | アポリポタンパク質b阻害剤としてのビアリールカルボキサミド化合物 |
CA2450957A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
KR100575944B1 (ko) | 2001-06-28 | 2006-05-02 | 화이자 프로덕츠 인코포레이티드 | 미소체 트리글리세라이드 전달 단백질(mtp) 및/또는아포지방단백질 b(apo b)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜 |
AU2002322585A1 (en) * | 2001-07-20 | 2003-03-03 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
WO2003013516A1 (en) * | 2001-08-10 | 2003-02-20 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
WO2003045921A1 (en) * | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
CA2472028C (en) * | 2002-02-01 | 2010-03-30 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
SG165154A1 (en) * | 2002-02-28 | 2010-10-28 | Japan Tobacco Inc | Ester compound and medical use thereof |
US7241774B2 (en) * | 2002-03-13 | 2007-07-10 | University Of Tennessee Research Foundation | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
JP2006516028A (ja) * | 2002-12-20 | 2006-06-15 | ファイザー・プロダクツ・インク | ミクロソームトリグリセリド輸送タンパク質阻害剤 |
WO2004056777A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
KR20050110017A (ko) | 2003-03-17 | 2005-11-22 | 니뽄 다바코 산교 가부시키가이샤 | S-'2-(''1-(2-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-2-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법 |
EP1669345A4 (en) * | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
WO2005118548A1 (en) | 2004-03-01 | 2005-12-15 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
JP5697296B2 (ja) | 2004-03-05 | 2015-04-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法 |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
AU2005297923B2 (en) * | 2004-10-25 | 2010-12-23 | Japan Tobacco Inc. | Solid medicinal preparation improved in solubility and stability and process for producing the same |
WO2006050999A2 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S | Methods of reducing body fat |
JP2006249022A (ja) | 2005-03-11 | 2006-09-21 | Sumitomo Chemical Co Ltd | 4−(2−メチルフェニル)ベンゾトリフルオライドの製造方法 |
BRPI0607555A2 (pt) | 2005-04-19 | 2009-09-15 | Surface Logix Inc | inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b |
WO2006129193A2 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
AU2007225273A1 (en) * | 2006-03-10 | 2007-09-20 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EA201100813A1 (ru) * | 2006-04-03 | 2012-06-29 | Сантарис Фарма А/С | Фармацевтическая композиция |
US20090042835A1 (en) * | 2006-06-02 | 2009-02-12 | Davis Roger A | Compositions and methods for ameliorating hyperlipidemia |
WO2007143164A1 (en) * | 2006-06-02 | 2007-12-13 | San Diego State University Research Foundation | Compositions and methods for ameliorating hyperlipidemia |
US20100216864A1 (en) * | 2006-10-09 | 2010-08-26 | Ellen Marie Straarup | RNA Antagonist Compounds for the Modulation of PCSK9 |
TW200831497A (en) * | 2006-10-12 | 2008-08-01 | Epix Delaware Inc | Carboxamide compounds and their use |
JO2653B1 (en) | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB |
EP2076487B1 (en) | 2006-10-24 | 2010-05-26 | Janssen Pharmaceutica N.V. | Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives |
ES2382009T3 (es) | 2006-12-01 | 2012-06-04 | Bristol-Myers Squibb Company | Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares |
WO2008075949A1 (en) * | 2006-12-20 | 2008-06-26 | Friesland Brands B.V. | Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms |
US20080161279A1 (en) * | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
US8580756B2 (en) * | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
CA2681406A1 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
EP2162451A4 (en) * | 2007-06-25 | 2012-04-18 | Neurogen Corp | PIPERAZINYL-OXOALKYL-TETRAHYDRO-BETA-CARBOLINE AND RELATED ANALOGUE |
WO2009027527A2 (en) * | 2007-08-30 | 2009-03-05 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of fabp4/ap2 |
ES2463665T3 (es) * | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
ES2575131T3 (es) | 2007-12-03 | 2016-06-24 | Obe Therapy Biotechnology | Inhibidores boropéptidos de enteropeptidasa y sus usos en tratamientos de obesidad, sobrepeso y/o enfermedades asociadas con un metabolismo anormal de la grasa |
JP2011506466A (ja) | 2007-12-11 | 2011-03-03 | 株式会社サイトパスファインダー | カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用 |
US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
US8361980B2 (en) * | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
ES2541442T3 (es) | 2008-08-01 | 2015-07-20 | Roche Innovation Center Copenhagen A/S | Modulación mediada por microARN de factores estimulantes de colonias |
EP2421970B1 (en) * | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
JP2016516804A (ja) | 2013-04-17 | 2016-06-09 | ファイザー・インク | 心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体 |
EP3591054A1 (en) | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Antisense oligomers and conjugates targeting pcsk9 |
WO2015065595A1 (en) | 2013-10-30 | 2015-05-07 | Trustees Of Dartmouth College | Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
WO2016064970A1 (en) * | 2014-10-22 | 2016-04-28 | The Board Of Regents Of The University Of Texas System | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof |
EP3911648A4 (en) | 2019-01-18 | 2022-10-26 | Astrazeneca AB | PCSK9 INHIBITORS AND METHODS OF USE THEREOF |
CN113292493A (zh) * | 2021-06-23 | 2021-08-24 | 上海立科化学科技有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5739135A (en) * | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
WO1996040640A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
-
1997
- 1997-11-03 AU AU46347/97A patent/AU716151B2/en not_active Ceased
- 1997-11-03 TR TR1999/01180T patent/TR199901180T2/xx unknown
- 1997-11-03 IL IL12974497A patent/IL129744A0/xx unknown
- 1997-11-03 EA EA199900416A patent/EA001539B1/ru not_active IP Right Cessation
- 1997-11-03 CN CN97180033A patent/CN1238764A/zh active Pending
- 1997-11-03 CA CA002272719A patent/CA2272719C/en not_active Expired - Fee Related
- 1997-11-03 JP JP52446498A patent/JP3270764B2/ja not_active Expired - Fee Related
- 1997-11-03 YU YU23499A patent/YU23499A/sh unknown
- 1997-11-03 EP EP97945048A patent/EP0944602A1/en not_active Withdrawn
- 1997-11-03 BR BR9714364A patent/BR9714364A/pt not_active Application Discontinuation
- 1997-11-03 SK SK654-99A patent/SK65499A3/sk unknown
- 1997-11-03 WO PCT/IB1997/001368 patent/WO1998023593A1/en not_active Application Discontinuation
- 1997-11-03 KR KR1019997004662A patent/KR100334567B1/ko not_active IP Right Cessation
- 1997-11-03 US US09/284,466 patent/US6121283A/en not_active Expired - Fee Related
- 1997-11-03 NZ NZ335162A patent/NZ335162A/xx unknown
- 1997-11-04 HN HN1997000144A patent/HN1997000144A/es unknown
- 1997-11-05 TW TW086116476A patent/TW502023B/zh not_active IP Right Cessation
- 1997-11-14 PA PA84416A patent/PA8441601A1/es unknown
- 1997-11-20 AP APAP/P/1997/001145A patent/AP804A/en active
- 1997-11-24 PE PE1997001062A patent/PE17199A1/es not_active Application Discontinuation
- 1997-11-25 ID IDP973763A patent/ID18995A/id unknown
- 1997-11-25 GT GT199700122A patent/GT199700122A/es unknown
- 1997-11-25 UY UY24789A patent/UY24789A1/es not_active Application Discontinuation
- 1997-11-26 MA MA24877A patent/MA26451A1/fr unknown
- 1997-11-26 AR ARP970105560A patent/AR010309A1/es unknown
- 1997-11-26 HR HR60/032,307A patent/HRP970642A2/hr not_active Application Discontinuation
- 1997-11-26 TN TNTNSN97193A patent/TNSN97193A1/fr unknown
- 1997-11-26 ZA ZA9710641A patent/ZA9710641B/xx unknown
- 1997-11-26 DZ DZ970208A patent/DZ2358A1/xx active
-
1999
- 1999-04-30 IS IS5040A patent/IS5040A/is unknown
- 1999-05-19 OA OA9900106A patent/OA11050A/en unknown
- 1999-05-26 BG BG108830A patent/BG108830A/bg unknown
- 1999-05-26 NO NO19992525A patent/NO312760B1/no unknown
- 1999-05-26 BG BG103434A patent/BG103434A/bg unknown
-
2002
- 2002-02-19 CN CN02105189A patent/CN1380289A/zh active Pending
- 2002-09-17 CZ CZ20023137A patent/CZ292160B6/cs not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG103434A (bg) | Амиди инхибиращи апо в-секреция/мтр, фармацевтичен състав и използването им | |
CA2356158A1 (en) | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications | |
WO1998040375A3 (en) | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | |
IL111455A0 (en) | Substituted heterocyclic carboxamide esters, theirpreparation and their use as pharmaceuticals | |
MX9702175A (es) | Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol. | |
IL111454A0 (en) | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals | |
CA2356422A1 (en) | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications | |
YU9802A (sh) | Inhibitori ćelijske adhezije | |
MY121399A (en) | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications | |
BG101209A (bg) | Хиполипидемични 1,4-бензотиазепин-1,1-диоксиди | |
MXPA01006472A (es) | Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares. | |
AU8995598A (en) | Product and method for the treatment of hyperlipidemia | |
CA2347117A1 (en) | Methods for inhibiting diabetic complications | |
CA2356157A1 (en) | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications | |
WO2004039453A3 (de) | 7h-dibenzo[b,g][1,5]dioxocin-5-on-derivate und ihre verwendung | |
ECSP972325A (es) | Amidas inhibidoras de la secrecion de apo b/mtp | |
CO4650034A1 (es) | Amidas inhibidoras de la secrecion de apo b/mtp | |
IL113074A (en) | Hypocholesterolemic antiatherosclerotic and hypotriglyceridemic pharmaceutical compositions comprising derivatives of mercaptoacetamido-oxopyrrolo (and pyrido) benzazepinecarboxylic acids | |
IL113076A (en) | Pharmaceutical hypocholesterolemic and hypotriglyceridemic compositions containing tricyclic dipeptide derivatives of alpha-(aminoalkanoylthio) benzenepropionic acid |